Please note that a publication can be assigned to several endpoints, i.e. the sum of publications from the individual thematic points and subpoints can be greater than the total sum of actual publications.
Authors | Year | Exposed system | Parameters | Magnetic flux density/field strength |
---|---|---|---|---|
Zeng Y et al. | 2017 | intact cell/cell culture, primary hippocampal neurons from rat embryos | 50/60 Hz, magnetic field | 2 mT |
Rajendra P et al. | 2012 | intact cell/cell culture, sheep primary lymphocytes | 50/60 Hz, magnetic field | 5–100 µT |
Ding Z et al. | 2017 | intact cell/cell culture, B95-8 cells (marmoset lymphocytes), BALB/3T3 cells (embryonal mouse fibroblasts) | 50/60 Hz, magnetic field, co-exposure | 2.3 mT |
Sanie-Jahromi F et al. | 2018 | - | 50/60 Hz, magnetic field, co-exposure | - |
Nasrabadi N et al. | 2018 | intact cell/cell culture, human retinal pigment epithelial cells | 50/60 Hz, signals/pulses, magnetic field | 1 mT |
Amiri M et al. | 2018 | intact cell/cell culture, human glioblastoma cell line (U-87) | 50/60 Hz, static magnetic field, magnetic field, co-exposure, also other exposures without EMF | - |
Phillips JL | 1986 | intact cell/cell culture, human colon carcinoma cell line (Colo 205) | electric field, magnetic field, 50/60 Hz | 0.1 mT |
Schimmelpfeng J et al. | 1997 | intact cell/cell culture, SV40-swiss-3T3 cells (mouse fibroblast cell line) and HL-60 cells (human acute myeloid leukaemia cell line) | magnetic field, 50/60 Hz | 2 mT |
Simko M et al. | 1998 | intact cell/cell culture, AFC cells (human amniotic fluid cell line) and SCL II cells (human squamous cell carcinoma cell line) | magnetic field, 50/60 Hz | 1 mT |
McNamee JP et al. | 2002 | animal, mouse/ICR, whole body | magnetic field, 50/60 Hz | 1 mT |
Robison JG et al. | 2002 | intact cell/cell culture, HL-60 (human acute myeloid leukaemia cells), HL-60R (human acute myeloid leukaemia cells with retinoic acid receptor-alhpa gene mutation) and Raji cells (human Burkitt lymphoma cells) | magnetic field, 50/60 Hz | 150 µT |
Pang L et al. | 2002 | intact cell/cell culture, K562 cells (human erythroleukemic cell line) | magnetic field, 50/60 Hz | 4.4–13 mT |
Santini MT et al. | 2003 | intact cell/cell culture, human osteosarcoma cell lines (MG-63 and Saos-2) | magnetic field, 50/60 Hz | 500 µT |
Pirozzoli MC et al. | 2003 | intact cell/cell culture, LAN-5 (human neuroblastoma cells) | magnetic field, 50/60 Hz | 1 mT |
Lee JS et al. | 2004 | animal, mouse/BALB/c, whole body | magnetic field, 50/60 Hz | 0.1–0.5 mT |
Ding GR et al. | 2004 | intact cell/cell culture, HL-60 (human acute myeloid leukaemia cells) | magnetic field, 50/60 Hz | 5 mT |
Santini MT et al. | 2005 | intact cell/cell culture, K562 cells (human erythroleukemic cell line) | magnetic field, 50/60 Hz | 1–5 mT |
Kroupova J et al. | 2007 | intact cell/cell culture, A549 (human adenocarcinoma cell line) | magnetic field, 50/60 Hz | 2 mT |
Lopucki M et al. | 2003 | isolated organ, human placentae (after delivery) | magnetic field, 50/60 Hz | 2 mT |
Guo H et al. | 2004 | intact cell/cell culture, SNU cells (human gastric adenocarcinoma cell line) | magnetic field, 50/60 Hz | 97 mT |
Kim YW et al. | 2009 | animal, mouse/BALB/c, whole body | magnetic field, 50/60 Hz | 14–200 µT |
Roushangar L et al. | 2007 | animal, rat/Wistar | magnetic field, 50/60 Hz | 3 mT |
Hisamitsu T et al. | 1997 | intact cell/cell culture, HL-60 and ML-1 cells (human acute myeloid leukaemia cell lines) and human peripheral blood lymphocytes and human peripheral blood polymorphonuclear cells | magnetic field, 50/60 Hz | 45 mT |
Kim J et al. | 2010 | intact cell/cell culture, HeLa cell line (human adenocarcinoma cell line) and IMR90 (human lung fibroblasts) | magnetic field, 50/60 Hz | 3–6 mT |
Basile A et al. | 2011 | intact cell/cell culture, human melanoma cell lines (M14 and A375), animal, mouse/BALB/c nu/nu mic with M14 xenografts, whole body | magnetic field, 50/60 Hz | 30 A/m |
This website uses cookies to provide you the best browsing experience. By continuing to use this website you accept our use of cookies.